1.   Liao R, Wu Y, Qin L, Jiang Z, Gou S, Zhou L, Hong Q, Li Y, Shi J, Yao Y, Lai L, Li Y, Liu P, Thiery JP, Qin D, Graf T, Liu X, Li P. BCL11B and the NuRD complex cooperatively guard T-cell fate and inhibit OPA1-mediated mitochondrial fusion in T cells. EMBO J. 2023 Sep 22:e113448.

2.   Cui Y, Yuan T, Wang Y, Zheng D1, Qin L, Li S, Jiang Z, Lin S, Guo W, Liang Z, Li Y, Yao Y, Liu X, Tang Q, Tu H, Zhang X, Tang Z, Tang Y, Huang L, Luo X, Wong N, Zhang Z, Qin D, Thiery J*, Xu K*, Li P*. T lymphocytes expressing the switchable chimeric Fc receptor CD64 exhibit augmented persistence and antitumor activity. Cell Reports. 2023 Jul 25;42(7):112797.

3.   Qin L, Cui Y, Yuan T, Chen D, Zhao R, Li S, Jiang Z, Wu Q, Long Y, Wang S, Tang Z, Pan H, Li X, Wei W, Yang J, Luo X, Zhang Z, Tang Q, Liu P, Weinkove R, Yao Y, Qin D, Thiery JP*, Li P*. Co-expression of a PD-L1-specific chimeric switch receptor augments the efficacy and persistence of CAR T cells via the CD70-CD27 axis. Nat Commun. 2022 Oct 13;13(1):6051.

4.   Jiang Z#, Cheng L#, Wu Z, Zhou L, Hong Q, Wu Q, Long Y, Huang Y, Xu G, Yao Y, Tang C, Zhang Z, Yang L, Luo W, Yang J, Gong L, Liu P, Chen X, Cui S, Zhang Q, Li Y*, Li P*. Transforming primary human hepatocytes into hepatocellular carcinoma with genetically defined factors. EMBO Rep. 2022 Jun 7;23(6):e54275.

5.   Li S#, Zhao R#, Zheng D, Qin L, Cui Y, Li Y, Jiang Z, Zhong M, Shi J, Li M, Wang X, Tang Z, Wu Q, Long Y, Hu D, Wang S, Yao Y, Liu S, Yang LH, Zhang Z, Tang Q, Liu P, Li Y*, Li P*. DAP10 integration in CAR-T cells enhances the killing of heterogeneous tumors by harnessing endogenous NKG2D. Mol Ther Oncolytics. 2022 Jun 6;26:15-26.

6.   Zheng D#, Wang X#, Cheng L, Qin L, Jiang Z, Zhao R, Li Y, Shi J, Wu Q, Long Y, Wang S, Tang Z, Wei W, Yang J, Li Y, Zhou H, Liu Q, Liu P, Chen X, Yao Y, Yang L, Li P*. The Chemokine Receptor CCR8 Is a Target of Chimeric Antigen T Cells for Treating T Cell Malignancies. Front Immunol. 2022 May 26;13:808347.

7.   Jiang Z#, Qin L#, Tang Y#, Liao R, Shi J, He B, Li S, Zheng D, Cui Y, Wu Q, Long Y, Yao Y, Wei Z, Hong Q, Wu Y, Mai Y, Gou S, Li X, Weinkove R, Norton S, Luo W, Feng W, Zhou H, Liu Q, Chen J, Lai L, Chen X, Pei D, Graf T, Liu X, Li Y, Liu P*, Zhang Z*, Li P*. Human induced-T-to-natural killer cells have potent anti-tumour activities. Biomark Res. 2022 Mar 24;10(1):13.

8.   Pang Z#. Shi J#, Qin L#, Chen A#, Tang Y, Yang H, Huang Y, Wu Q, Li X, He B, Li T, Liang B, Zhang J, Gao B, Liu M, Feng Y, Ye X, Chen X, Wang L, Yu Tian1, Hao Li1, Li J, Hu H, He J, Hu Y, Zhi C, Tang Z, Gong Y, Xu F, Xu L, Fan W, Zhao M, Chen D, Lian H*, Yang L*, Li P*, Zhang Z*. IL-7 and CCL19-secreting CAR-T cell therapy for tumors with positive glypican-3 or mesothelin. J Hematol Oncol. 2021 Jul 29;14(1):118.

9.   Zhao, R#., Cui, Y#., Zheng, Y., Li, S., Lv, J., Wu, Q., Long, Y., Wang, S., Yao, Y., Wei, W., Yang, J., Wang, B. C., Zhang, Z., Zeng, H., Li, Y*., & Li, P*. Human Hyaluronidase PH20 Potentiates the Antitumor Activities of Mesothelin-Specific CAR-T Cells Against Gastric Cancer, Front Immunol. 2021 Jul 13;12:660488.

10. Jiang Z#, Liao R#, Lv J#, Li S, Zheng D, Qin L, Wu D, Chen S, Long Y, Wu Q, Wang S, Lin S, Huang X, Tang Z, Shi P, Zhou H, Liu Q, Zhao R, Li Y, Jie Y, Wei W, Lai P, Du X, Cui S, Weinkove R, Liu P, Pei D, Yao Y*, Li P*. IL-6 trans-signaling promotes the expansion and anti-tumor activity of CAR T cells. Leukemia. 2021 May;35(5):1380-1391.

11. Zhao R#, Cui Y#, Zheng Y, Li S, Lv J, Wu Q, Long Y, Wang S, Yao Y, Wei W, Yang J, Wang B, Zhang Z, Zeng H, Li Y*, Li P*. Human hyaluronidase PH20 potentiates the antitumor activities of mesothelin-specific CAR-T cells against gastric cancer. Front Immunol. (corresponding author).

12. Lai P#, Chen X#, Qin L#, Jiang Z, Luo C, Huang X, Wu S, Ling W, Wang Y, Wang J, Deng C, Huang L, Zeng L, Lu Z, Zhong L, Liao P, Li M, Chen D, Geng S, Wu P, Tang Z, Pei D, Du X*, Li P*, Weng J*. The efficacy and safety of CAR-T cell therapy in patients with refractory ALL and concomitant HBV infection. Leukemia. 2020 Oct;34(10):2790-2793. 2020 Jul 6. PMID: 32632097.（corresponding author）IF= 8.665

13. Qin L#, Zhao R, Chen D, Wei X, Wu Q, Long Y, Jiang Z, Li Y, Wu H, Zhang X, Wu Y, Cui S, Wei W, Yao H, Liu Z, Cao S, Yao Y*, Zhang Z*, Li* P. Chimeric antigen receptor T cells targeting PD-L1 suppress tumor growth. Biomarker Research. 2020;8:19. （corresponding author） IF= 4.866

14. Wu D, Lv J, Zhao R, Wu Z, Zheng D, Shi J, Lin S, Wang S, Wu Q, Long Y, Li* P, Yao Y*. PSCA is a target of chimeric antigen receptor T cells in gastric cancer. Biomark Res. 2020 Jan 28; 8:3. （corresponding author） IF= 4.866

15. Lai Y#, Weng# J, Wei X, Qin L, Lai P, Zhao R, Jiang Z, Li B, Lin S, Wang S, Wu Q, Tang C, liu P, Pei D, Yao Y, Du* X, and Li* P. Toll-like Receptor 2 Costimulation Potentiates the Antitumor Efficacy of CAR T Cells. Leukemia. 2017 Aug 3. （corresponding author）IF= 8.665

16. Lv J#, Zhao R#, Wu D#, Zheng D, Wu Z, Shi J, Wei X, Wu Q, Long Y, Lin S, Wang S, Wang Z, Li Y, Chen Y, He Q, Chen S, Yao H, Liu Z, Tang Z, Yao Y, Pei D, Liu P, Zhang X, Zhang Z, Cui S, Chen R, Peng Li*. Mesothelin is a target of chimeric antigen receptor T cells for treating gastric cancer. J Hematol Oncol. 2019 Feb 18;12(1):18. （corresponding author） IF=11.059

17. Lin S#, Huang G#, Cheng L#, Li Z, Xiao Y, Deng Q, Jiang Y, Li B, Lin S, Wang S, Wu Q, Yao H, Cao S, Li Y, Liu P, Wei W, Pei D, Yao Y, Wen Z, Zhang X, Wu Y, Zhang Z, Cui S, Sun X, Qian X*, Li Peng*. Establishment of peripheral blood mononuclear cell-derived humanized lung cancer mouse models for studying efficacy of PD-L1/PD-1 targeted immunotherapy. MAbs. 2018 Oct 02. 10:8:1301-1311. （corresponding author） IF=4.634

18. Zhao, R.; Cheng, L.; Jiang. Z.; Wei. X.; Li. B.; Wu. Q.; Wang. S.; Lin. S.;  Long. Y.; Zhang. X.; Wu. Y.; Du. X.; Pei. D.; Liu. P.; Li. Y.; Cui. S.; Yao. Y* and Li. Peng*, DNAX-activating protein 10 co-stimulation enhances the anti-tumor efficacy of chimeric antigen receptor T cells," OncoImmunology. 02 Nov 2018. 2019, 8:1 （corresponding author） IF=5.869

19. Weng, J#.; Lai, P#.; Qin, L#.; Lai, Y.; Jiang, Z.; Luo, C.; Huang, X.; Wu, S.; Shao, D.; Deng, C.; Huang, L.; Lu, Z.; Zhou, M.; Zeng, L.; Chen, D.; Wang, Y.; Chen, X.; Geng, S.; Robert, W.; Tang, Z.; He, C.; Peng Li*; Du, X*., A novel generation 1928zT2 CAR T cells induce remission in extramedullary relapse of acute lymphoblastic leukemia. J Hematol Oncol 2018, 11 (1), 25. （corresponding author）IF= 11.059

20. Lin S#, Huang G#, Xiao Y, Sun W, Jiang Y, Deng Q, Peng M, Wei X, Ye W, Li B, Lin S, Wang S, Wu Q, Liang Q, Li Y, Zhang X, Wu Y, Liu P, Pei D, Yu F, Wen Z, Yao Y, Wu D*, Peng Li*. CD215+ Myeloid Cells Respond to Interleukin 15 Stimulation and Promote Tumor Progression. Front Immunol. 2017 Dec 4;8:1713. IF=5.085 （corresponding author）

21. Jiang Z#, Wu D, Ye W, Weng J, Lai P, Shi P, Guo X, Huang G, Deng Q, Tang Y, Zhao H, Cui S, Lin S, Wang S, Li B, Wu Q, Li Y, Liu P, Pei D, Du X, Yao Y*, Li* P. Defined, serum/feeder-free conditions for expansion and drug screening of primary B-acute lymphoblastic leukemia. Oncotarget. 2017 Nov 15;8(63):106382-106392.（corresponding author）

22. Wei X#, Lai Y, Li B, Qin L, Xu Y, Lin S, Wang S, Wu Q, Liang Q, Huang G, Deng Q, Liu P, Wu D, Lai L, Yao Y*, Peng Li*. CRISPR/Cas9-Mediated Deletion of Foxn1 in NOD/SCID/IL2rg-/- Mice Results in Severe Immunodeficiency. Sci Rep. 2017 Aug 10;7(1):7720. IF=3.998 （corresponding author）

23. Li Y, Wang Y. Zhou Y, Li J, Chen K, Zhang L, Deng M, Deng S, Li Peng*, Xu B*.Cooperative effect of chidamide and chemotherapeutic drugs induce apoptosis by DNA damage accumulation and repair defects in acute myeloid leukemia stem and progenitor cells. Clin Epigenetics. 2017 Aug 14;9:83. IF=5.028（corresponding author）

24. Wei X#, Lai Y#, Li J, Qin L, Xu Y, Zhao R, Li B, Lin S, Wang S, Wu Q, Liang Q, Peng M, Yu F, Li Y, Zhang X, Wu Y, Liu P, Pei D, Yao Y*&Li* P. PSCA and MUC1 in Non-small-cell Lung Cancer as Targets of Chimeric Antigen Receptor T cells. Oncoimmunology. 2017 Feb 6;6(3):e1284722.（corresponding author） IF=5.869

25. Qin L#; Lai Y#; Zhao R; Wei X; Weng J; Lai P; Li B; Lin B; Wang S; Wu Q; Liang Q; Li Y; Zhang X; Wu Y; Liu P; Yao Y; Pei D; Du X; Li* P. Incorporation of a hinge domain improves the expansion of chimeric antigen receptor T cells. J Hematol Oncol. 2017; 10: 68.（corresponding author） IF=11.059

26. Jiang Z#, Jiang X#, Chen S, Lai Y, Wei X, Li B, Lin S, Wang S, Wu Q, Liang Q, Liu Q, Peng M, Yu F, Weng J, Du X, Pei D, Liu P, Yao Y, Xue P*,Li P*., Anti-GPC3 CAR T cells suppress the growth of tumour cells in patient-derived xenografts of hepatocellular carcinoma. Front. Immunol. 2017 Jan 11;7:690.（corresponding author）IF=5.085

27. Jiang Z#; Deng M#; Wei X; Ye W; Xiao Y; Lin S; Wang S; Li B; Liu X; Zhang G; Lai P; Weng J; Wu D; Chen H; Wei W; Ma Y; Li Y; Liu P; Du X; Pei D; Yao Y; Xu B*;Li P*.Heterogeneity of CD34 and CD38 expression in adult acute B lymphoblastic leukemia cells is reversible and not hierarchically organized. Journal of Hematology & Oncology. 2016 Sep 22;9(1):94.. IF=11.059（corresponding author）

28. Zhao H, Shi P, Deng M, Jiang Z, Li Y, Kannappan V, Wang W, Peng Li, Xu B. Low dose triptolide reverses chemoresistance in adult acute lymphoblastic leukemia cells via reactive oxygen species generation and DNA damage response disruption. Oncotarget. 2016 Nov 19.（corresponding author）

29. Ye W#, Jiang Z#, Lu X, Ren X, Deng M, Lin S, Xiao Y, Lin S, Wang S, Li B, Zheng Y, Lai P, Weng J, Wu D, Ma Y, Chen X, Wen Z, Chen Y, Feng X, Li Y, Liu P, Du X, Pei D, Yao Y, Xu B, Ding K*,Li P*.GZD824 suppresses the growth of human B cell precursor acute lymphoblastic leukemia cells by inhibiting the SRC kinase and PI3K/AKT pathways. Oncotarget. July 28, 2016.（corresponding author）

30. Zhang L, Zhou Y, Chen K, Shi P, Li Y, Deng M, Jiang Z, Wang X, Li P*, Xu B*. The pan-Bcl2 Inhibitor AT101 Activates the Intrinsic Apoptotic Pathway and Causes DNA Damage in Acute Myeloid Leukemia Stem-Like Cells. Targeted Oncology. 2017 Jul 14.（corresponding author）IF= 4.036

31. Li Y, Chen K, Zhou Y, Xiao Y, Deng M, Jiang Z, Ye W, Wang X, Wei X, Li J, Liang J, Zheng Z, Yao Y, Wang W, Li P*, Xu B*.A New Strategy to Target Acute Myeloid Leukemia Stem and Progenitor Cells Using Chidamide, a Histone DeacetylaseInhibitor. Current Cancer Drug Targets. 2015;15(6):493-503. (corresponding author) IF= 2.912

32. Deng M#, Jiang Z#, Li Y, Zhou Y, Li J, Wang X, Yao Y, Wang W, Li Peng*, Xu B*. Effective elimination of adult B-lineage acute lymphoblastic leukemia by disulfiram/copper complex in vitro and in vivo in patient-derived xenograftmodels. Oncotarget. 2016 May 17. (corresponding author)

33. Sun W, Lai Y, Li H, Nie T, Kuang Y, Tang X, Li K, P. Rod Dunbar, Xu A, Li P*, Donghai Wu*. High level expression and purification of active recombinant human interleukin-15 in Pichiapastoris. Journal of Immunological Methods.2016 Jan;428:50-57. (corresponding author) IF= 1.901

34. Ye W#, Jiang Zhiwu#, Li GX, Xiao Y, Lin S, Lai Y, Wang S, Li B, Jia B, Li Y, Huang ZL, Li J, Feng F, Li S, Yao H, Liu Z, Cao S, Xu L, Li Y, Wu D, Zeng L, Zhong M, Liu P, Wen ZS, Xu B, Yao Y, Pei D*, Li Peng*.Quantitative evaluation of the immunodeficiency of a mouse strain by tumor engraftments. J Hematol Oncol.2015 May 29;8:59.（corresponding author）IF=11.059

35. W Li, ZW Jiang, TZ Li, X Wei, Yi Zheng, D Wu, L Yang, S Chen, B Xu, M Zhong, J Jiang, Y Hu, H Su, M Zhang, X Huang, S Geng, J Weng, X Du, P Liu, Y Li, H Liu, Yao Yao* and Peng Li*. Genome-wide analyses identify KLF4 as an important negative regulator in T-cell acute lymphoblastic leukemia through directly inhibiting T-cell associated genes. Molecular Cancer. 2015 Feb 3;14:26.（corresponding author）IF= 15.302

36. Y Xiao, X Wei, Z Jiang, X Wang, W Ye, X Liu, M Zhang, Y Xu, D Wu, L Lai, H Yao, Z Liu, S Cao, P Liu, B Xu, Y Li, Y Yao, D Pei* and Peng Li*. Loss of Angiopoietin-like 7 diminishes the regeneration capacity of hematopoietic stem and progenitor cells. J Hematol Oncol. 2015 Feb 6;8(1):7.（corresponding author）IF=11.059

37. Xiao Y, Jiang Z, Li Y, Ye W, Jia B, Zhang M, Xu Y, Wu D, Lai L, Chen Y, Chang Y, Huang X, Liu H, Qing G, Liu P, Li Y, Xu B, Zhong M, Yao Y, Pei D, Peng Li*. ANGPTL7 regulates the expansion and repopulation of human hematopoietic stem and progenitor cells. Haematologica. 2015 May;100(5):585-94.（corresponding author）IF= 7.116

38. Li P, Burke S et al, Liu P*. Reprogramming of T Cells to Natural Killer-Like Cells upon Bcl11b Deletion. Science. 2010 Jul 2;329(5987):85-9. （First author）IF= 41.845

39. Lai Y#, Wei X, Lin S, Qin L, Cheng L, Li P*.Current status and perspectives of patient-derived xenograft models in cancer research. J Hematol Oncol. 2017 May 12;10(1):106. Review.（corresponding author）IF=11.059

40. Lv J, Li P*.Mesothelin as a biomarker for targeted therapy. Biomark Res. 2019 Aug 23; 7: 18. Review. （corresponding author） IF= 4.866

41. Qin L, Zhao R , Li P*., Incorporation of functional elements enhances the antitumor capacity of CAR T cells. Exp Hematol Oncol. 2017 Oct 11;6:28. Review.（corresponding author）

42. Zhao R, Lai Y, Li P*., Kruppel-Like Factor 4: From Physiological Functions to Tumor Therapy. Forum on Immunopathological Diseases and Therapeutics. Volume 7, 2016 Issue 1-2. Review.（corresponding author）

43. Jiang Z, Wu D, Lin S and Li P*., CD34 and CD38 are prognostic biomarkers for acute B lymphoblastic leukemia. Biomarker Research. 2016 4:23. Review.（corresponding author） IF= 4.866

44. Lin S, Zhao R, Xiao Y, Li P*. Mechanisms determining the fate of hematopoietic stem cells. Stem Cell Investigation. 2015;2:10. Review. (corresponding author)

45. Li P, Xiao Y, Liu Z, Liu P. Using mouse models to study function of transcriptional factors in T cell development.  Cell Regeneration. 2012 Oct 10;1(1):8. Review.（First author）